Loading clinical trials...
Loading clinical trials...
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
R-Pharm
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
NCT06287723 · Colorectal Cancer, Liver Metastases, and more
NCT04521764 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, and more
NCT05774951 · Breast Cancer, Early Breast Cancer
Local Institution
La Verne, California
Local Institution
Meriden, Connecticut
Local Institution
Jacksonville, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions